{"id":58757,"date":"2026-02-19T01:08:24","date_gmt":"2026-02-19T05:08:24","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/jpmorgan-adjusts-price-targets-for-celanese-and-charles-river-following-q4-results\/58757\/"},"modified":"2026-02-19T01:08:24","modified_gmt":"2026-02-19T05:08:24","slug":"jpmorgan-adjusts-price-targets-for-celanese-and-charles-river-following-q4-results","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/jpmorgan-adjusts-price-targets-for-celanese-and-charles-river-following-q4-results\/58757\/","title":{"rendered":"JPMorgan Adjusts Price Targets for Celanese and Charles River Following Q4 Results"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>JPMorgan raised its price target for Celanese Corp (<a href=\"\/stock\/CE\">CE<\/a>) to $53 from $40<\/strong>, reflecting a more optimistic outlook on the company&#39;s cash flow generation despite recent earnings misses.<\/li>\n<li><strong>Charles River Laboratories (<a href=\"\/stock\/CRL\">CRL<\/a>) saw its price target trimmed to $165 from $190<\/strong> by JPMorgan, following a cautious 2026 outlook and a &quot;Neutral&quot; rating maintenance.<\/li>\n<li><strong>Divergent sector trends<\/strong> are emerging as industrial chemical firms like Celanese focus on deleveraging and cost-cutting, while life sciences firms like Charles River face a slower-than-expected recovery in biotech demand.<\/li>\n<li><strong>Celanese targets $650 million to $750 million in free cash flow for 2026<\/strong>, a key metric driving the analyst&#39;s upward revision.<\/li>\n<\/ul>\n<h2>JPMorgan Bullish on Celanese Recovery Despite Earnings Miss<\/h2>\n<p>JPMorgan has significantly increased its price target for Celanese Corp (<a href=\"\/stock\/CE\">CE<\/a>), moving the figure to <strong>$53 from a previous $40<\/strong>. This adjustment comes even after the chemical giant reported fourth-quarter adjusted earnings of <strong>$0.67 per share<\/strong>, which fell short of the consensus estimate of $0.89. The company&#39;s revenue also declined <strong>7% year-over-year<\/strong> to $2.20 billion, primarily due to lower volumes and pricing pressures in its Acetyl Chain segment.<\/p>\n<p>Despite the immediate earnings headwinds, <em>analysts are focusing on the company&#39;s aggressive deleveraging strategy and cost-improvement initiatives<\/em>. Celanese management has set a 2026 free cash flow target of <strong>$650 million to $750 million<\/strong>, signaling confidence in its ability to generate liquidity. The market is increasingly viewing the stock as a recovery play, with the new target suggesting that JPMorgan sees a path toward stabilized margins as industrial demand potentially troughs in the Western Hemisphere.<\/p>\n<h2>Charles River Laboratories Faces Cautious Outlook and Target Cut<\/h2>\n<p>In a contrasting move, JPMorgan lowered its price objective for Charles River Laboratories (<a href=\"\/stock\/CRL\">CRL<\/a>) to <strong>$165 from $190<\/strong>. The firm maintained its <strong>Neutral rating<\/strong> on the stock, reflecting concerns over the pace of recovery in the contract research organization (CRO) sector. While Charles River reported a fourth-quarter earnings beat with <strong>$2.39 per share<\/strong> against the $2.33 expected, its forward-looking guidance for 2026 disappointed some investors.<\/p>\n<p>The company&#39;s 2026 outlook projects organic revenue growth to range from <strong>a 1% decrease to flat<\/strong>, a sign that <em>biotech R&amp;D spending remains constrained<\/em>. Although management expressed &quot;cautious optimism&quot; for a stronger second half of 2026, the near-term visibility remains clouded by segment-specific weakness in Discovery and Safety Assessment (DSA). JPMorgan&#39;s target reduction highlights the <em>ongoing valuation pressure<\/em> on life sciences services as the industry recalibrates following the post-pandemic slowdown.<\/p>\n<h2>Shifting Sentiment in Industrial vs. Life Sciences Sectors<\/h2>\n<p>The adjustments by JPMorgan underscore a broader shift in institutional sentiment between cyclical industrials and healthcare services. For Celanese Corp (<a href=\"\/stock\/CE\">CE<\/a>), the focus has shifted from top-line growth to <strong>operational efficiency and debt reduction<\/strong>, which appears to be winning over analysts looking for value in a volatile macro environment.<\/p>\n<p>Conversely, for Charles River Laboratories (<a href=\"\/stock\/CRL\">CRL<\/a>), the market is demanding more concrete evidence of a <strong>sustained rebound in drug-development demand<\/strong>. With the stock trading near its 52-week lows, the lower price target reflects a &quot;wait-and-see&quot; approach from Wall Street as the company navigates a transition under a new CEO and integrates recent acquisitions like K.F. (Cambodia) to bolster its supply chain.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways JPMorgan raised its price target for Celanese Corp (CE) to $53 from $40, reflecting a more optimistic outlook [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[4018,4100,4380,5273,5337,6358,17085,17384,17385],"class_list":["post-58757","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-ce","tag-crl","tag-stock-market","tag-jpmorgan","tag-dsa","tag-price-target","tag-cro","tag-celanese","tag-charles-river-laboratories"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/58757","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=58757"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/58757\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=58757"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=58757"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=58757"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}